FDG PET/CT监测微卫星高度不稳定转移性乳腺癌PD-L1阻断治疗
FDG PET/CT显示12个月内达到完全代谢缓解,提示其可用于监测主动免疫治疗反应。
要点
- 微卫星高度不稳定/错配修复缺陷可预测帕博利珠单抗对转移性实体瘤的疗效
- FDG PET/CT在12个月内显示完全代谢缓解
- FDG PET/CT有助于监测主动免疫治疗的疗效
核心结论
- FDG PET/CT在帕博利珠单抗治疗的微卫星高度不稳定转移性乳腺癌中显示12个月内完全代谢缓解,可用于监测主动免疫治疗反应。
主要发现
- FDG PET/CT显示12个月内达到完全代谢缓解。
关键数值与推荐
- 复发灶活检示微卫星高度不稳定,作为帕博利珠单抗治疗的依据;FDG PET/CT示12个月内完全代谢缓解。
临床怎么用
- 对微卫星高度不稳定、接受PD-L1抑制剂治疗的转移性乳腺癌患者,可用FDG PET/CT动态监测代谢缓解情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Microsatellite instability-high/mismatch repair deficiency is one of biomarkers predicting the response to pembrolizumab, an immune checkpoint inhibitor for metastatic solid tumors. A 44-year-old woman with stage IIIC right breast cancer was treated with mastectomy and axillary node dissection after primary systemic chemotherapy followed by radiation, chemotherapy, and hormonal therapy. Eighteen months after surgery, recurrent diseases were revealed and refractory to multiple treatments. The recurrent site biopsy showed microsatellite instability-high, and programmed cell death ligand-1 inhibitor pembrolizumab was administrated. FDG PET/CT showed complete metabolic response over 12 months and is useful to monitor the response of active immunotherapy.
引用
- Kawamata A, Sasada S, Emi A, et al. Monitoring of Programmed Cell Death Ligand-1 Blockade Using FDG PET/CT for Microsatellite Instability-High Metastatic Breast Cancer. Clin Nucl Med. 2022. PMID: 34593689. doi:10.1097/RLU.0000000000003950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。